Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH)

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Fi...

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...

Over the past six months, Amphastar Pharmaceuticals has been a great trade, beating the S&P 500 by 11.4%. Its stock price has climbed to $24.97, representing...

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q2 generic pharmaceuticals e...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

New product launches drove 5% revenue growth and margin expansion.

Amphastar Pharmaceuticals delivered results in Q2 that surpassed Wall Street expectations, reflecting continued strength across its diversified product portf...

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 5.4% year on y...

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is addressing an FDA warning letter at its IMS subsidiary and continuing investments in its pipeline and U.S

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 5.4% year o...

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting results this Thursday after market hours. Here’s what to look for. Amphastar ...

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Amphastar Pharmaceuticals has gotten torched over the last six months - since January 2026, its stock price has dropped 27.6% to $18.92 per share. This was p...

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...